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OBJECTIVES We sought to determine whether non–potassium-sparing diuretics (PSDs) in the absence of
a PSD may result in progressive heart failure (HF).
BACKGROUND Angiotensin-converting enzyme (ACE) inhibitors incompletely suppress ACE activity in HF
patients. Furthermore, non-PSDs are activators of aldosterone secretion. We reasoned that
non-PSDs, in the absence of a PSD, might result in progressive HF.
METHODS In the 6,797 patients in the Studies Of Left Ventricular Dysfunction (SOLVD), we
compared the risk of hospitalization for, or death from, HF between those taking a PSD and
those who were not, adjusting for known covariates.
RESULTS The risk of hospitalization from worsening HF in those taking a PSD relative to those taking
only a non-PSD was 0.74 (95% confidence interval [CI] 0.55 to 0.99; p  0.047). The
relative risk for cardiovascular death was 0.74 (95% CI 0.59 to 0.93; p  0.011), for death
from all causes 0.73 (95% CI 0.59 to 0.90; p  0.004), and for hospitalization for, or death
from, HF 0.75 (95% CI 0.58 to 0.97; p  0.030). Compared with patients not taking any
diuretic, the risk of hospitalization or death due to worsening HF in patients taking
non-PSDs alone was significantly increased (risk ratio [RR]  1.31, 95% CI 1.09 to 1.57; p
 0.0004); this was not observed in patients taking PSDs with or without a non-PSD (RR
 0.99, 95% CI 0.76 to 1.30; p  0.95).
CONCLUSIONS The use of PSDs in HF patients is associated with a reduced risk of death from, or
hospitalization for, progressive HF or all-cause or cardiovascular death, compared with
patients taking only a non-PSD. (J Am Coll Cardiol 2003;42:705–8) © 2003 by the
American College of Cardiology Foundation
Pharmacologic antagonists of the neurohormonal response
to heart failure (HF) reduce death due to progressive left
ventricular dysfunction (1–7). The Randomized ALdactone
Evaluation Study (RALES) demonstrated reduced HF
mortality with complete suppression of aldosterone secre-
tion effected by adding spironolactone to an angiotensin-
converting enzyme (ACE) inhibitor (3).
See page 709
Sudden cardiac death is increased when non-PSDs are
used without PSDs in HF (8), even when no clinically
significant difference in serum potassium is present in
patients taking PSDs, compared with those only taking
non-PSDs. Because aldosterone secretion causes pathologic
remodeling, treatment with non-PSD alone likely increased
the underlying arrhythmogenic substrate. We reasoned that
non-PSDs, in the absence of a PSD, might result in
progressive HF. This study compares the rates of death or
HF hospitalization in the Studies Of Left Ventricular
Dysfunction (SOLVD) between patients taking a PSD at
randomization and those who were not.
METHODS
Study design. The SOLVD study has been described
previously (9,10). Briefly, 6,797 symptomatic and asymp-
tomatic patients with a left ventricular ejection fraction
0.36 were randomly assigned to double-blinded treatment
with enalapril or placebo. Only drug class was ascertained;
specific medications were not recorded.
Statistical analysis. Incidence rates were compared using
the result that if X and Y have Poisson distributions, the
conditional distribution of X, given X  Y  n is binomial
with parameters n and p  PYR(X)/(PYR[X]  PYR[Y])
for equal incidence rates. The Cox proportional hazards
regression model was applied to estimate hazard ratios for
hospitalization and/or death from worsening heart failure
and death from cardiovascular disease and any cause. The
models included those co-variates recorded at baseline that
were judged as likely predictors of these events (Table 1).
The rates per 100 person-years of follow-up for each of the
previously defined events were calculated for each of the
four patterns of diuretic use: 1) no diuretic use (n  3,915)
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(omitted in later analyses); 2) PSD only (n  68); and 3)
non-PSD only (n  2469); and 4) both types of diuretic (n
 338). Group 2 was too small to permit a meaningful test
of an interactive effect from taking both types of diuretic.
The definitive comparison for evaluating the effect of using
a PSD was made by estimating the risks of those patients in
groups 2 and 4 relative to those in group 3, using the
aforementioned Cox model. Analyses were performed using
version 6.12 of PC SAS (SAS Institute, Cary, North
Carolina).
RESULTS
Baseline characteristics. At baseline (Table 1), compared
with patients not taking any diuretic, patients taking diuret-
ics were older and more often female, had a lower left
ventricular ejection fraction, higher New York Heart Asso-
ciation functional class, and higher creatinine levels, and
were more frequently taking digitalis and anti-arrhythmic
drugs.
Distribution of events by diuretic use. Rates of hospital-
ization for HF, death from cardiovascular disease, death
from all causes, and either hospitalization or death due to
worsening HF in all baseline diuretic use pattern groups
appear in Table 2. All are significantly higher for patients
taking a diuretic than for those who were not (p  0.01 for
all events). The event rates for those patients taking a PSD
are significantly lower than for those taking only a non-PSD
(p  105 to p  0.0008).
Multivariate analysis. Table 3 shows the risks for the same
set of events as in Table 2, after adjusting for known
covariates. Compared with patients not taking any diuretic,
the risk of hospitalization for, or death from, worsening HF
in patients taking non-PSDs alone was significantly in-
creased (risk ratio [RR]  1.31, 95% confidence interval
[CI] 1.09 to 1.57; p 0.004). In patients taking PSDs with
or without a non-PSD, this relative risk was not signifi-
cantly elevated (RR 0.99, 95% CI 0.76 to 1.30; p 0.71).
Table 4 shows the risks (adjusted for the covariates listed
earlier) for the four outcomes in Table 3 in patients taking
a PSD relative to those taking only a non-PSD. They show
significant reductions in the risks of hospitalization, death,
or both, due to worsening HF, as well as death from
cardiovascular disease and all causes, when the patient is
taking a PSD.
DISCUSSION
This study shows that, in patients with moderate or severe
left ventricular dysfunction, the use of a PSD is associated
with a reduced risk of death or hospitalization due to
progressive HF, relative to patients taking only a non-PSD.
Potential mechanisms. In HF, initially compensatory
molecules are released, eventually contributing to progres-
sive left ventricular dysfunction (1,2,4–6). An important
component of this neurohormonal response is activation of
Table 1. Baseline Characteristics*
Variable
Baseline Diuretic Use
None
(n  3,915)
PSD Only
(n  68)
Non-PSD Only
(n  2,469)
Both
(n  338)
Age (yrs) 59  10 62  9 61  10 61  10
Gender (female) 11% 12% 20% 17%
Ejection fraction (%) 28  6 25  7 25  7 25  7
Systolic BP (mm Hg) 125  16 127  17 126  18 128  18
Diastolic BP (mm Hg) 78  9 78  9 77  11 78  10
Creatinine (mg/dl) 1.14  0.26 1.23  0.26 1.25  0.34 1.24  0.25
NYHA class (%2) 3 19 26 20
Beta-blocker (%) 23 25 10 14
Aspirin (%) 56 48 33 30
Anticoagulant (%) 12 10 15 18
Digitalis (%) 16 28 58 52
Antiarrhythmic (%) 16 25 21 18
Potassium supplement (%) 1 10 58 14
Ever smoked (%) 80 76 76 81
Diabetes (%) 15 12 26 22
Hypertension (%) 30 54 51 51
Angioplasty (%) 59 50 55 59
Previous MI (%) 82 65 64 69
*All characteristics (as mean values [SD] or percentages) differed significantly (p  0.001) among the four patterns.
BP  blood pressure; MI  myocardial infarction; NYHA  New York Heart Association; PSD  potassium-sparing
diuretic.
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CI  confidence interval
HF  heart failure
PSD  potassium-sparing diuretic
RALES  Randomized ALdactone Evaluation Study
RR  risk ratio
SOLVD  Studies Of Left Ventricular Dysfunction
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the renin-angiotensin-aldosterone system. In HF patients,
there is as much as a 20-fold increase in the aldosterone level
(11,12). Aldosterone causes reactive perivascular and inter-
stitial myocardial fibrosis (13) that can impair both systolic
and diastolic function (12,14) and serve as a substrate for
ventricular arrhythmias (5,14,15). These effects can be
prevented by spironolactone (1,14). In the RALES sub-
study, the greatest benefit from spironolactone occurred in
the patients with the highest baseline measures of collagen
synthesis and cardiac fibrosis (16). Other PSDs that are not
direct antagonists of aldosterone also appear to have bene-
ficial myocardial effects. Amiloride, for instance, prevents
aldosterone-mediated myocyte necrosis and replacement
fibrosis (17). The exact etiology of these positive effects
remains unclear; it may be due to a direct effect on the
Na/H exchanger, which amiloride antagonizes, versus
prevention of intracellular potassium depletion. If the main-
tenance of potassium homeostasis is the critical mechanism
behind these findings, then potassium depletion secondary
to non-PSDs, per se, represents a potential effector of
myocardial necrosis and fibrosis, which PSDs could prevent,
whether they directly antagonize aldosterone or not.
Elevated aldosterone levels occur in HF patients, despite
treatment with ACE inhibitors (2,18–21). Aldosterone
elimination is reduced in HF due to reduced hepatic
clearance (22,23). Also, tolerable ACE inhibitor doses may
not fully suppress aldosterone secretion (2,18–21). Further,
peripheral mechanisms that are not suppressed by ACE
inhibitors contribute to angiotensin II production (24,25).
Importantly, activation of angiotensin-independent aldoste-
rone secretion is stimulated by sodium losses caused by loop
diuretics (25,26). This mechanism could explain the role of
non-PSDs in causing progressive HF and, therefore, the
therapeutic benefit of aldosterone antagonists and other
PSDs.
This is the first report demonstrating increased mortality
from progressive HF in patients treated with only a non-
PSD, compared with those treated with a PSD. The
RALES study demonstrated that all-cause mortality and
progressive HF mortality are reduced by treatment with the
aldosterone antagonist spironolactone (3). This beneficial
effect was additive to ACE inhibitor treatment, consistent
with the failure of ACE inhibitors to fully suppress aldo-
sterone production.
Clinical implications. The American College of Cardiol-
ogy/American Heart Association guidelines for HF treat-
ment recommend diuretics for treating fluid overload (27).
Our data suggest that HF treatment with non-PSDs may
cause more rapid HF progression, and that this can be
aborted by co-treatment with a PSD. Although many
patients should be taking spironolactone because of the
RALES results, a PSD should be added to the regimen of
other patients being treated with a non-PSD.
Study limitations. This study is retrospective and, there-
fore, not definitive proof that non-PSDs cause progressive
HF. However, the SOLVD database is extensive, and all
available co-variates and confounders were considered in the
multivariate analysis. The number of patients taking only a
PSD was too small to provide a powerful test of the
interaction effect of taking both diuretic types on the risk of
the end points considered. Nevertheless, we believe that the
results of our comparisons of patients taking both types of
diuretics with those taking only non-PSDs are robust.
Because the diuretic dosage was not available, we cannot
draw conclusions about a dose-response relationship. Also,
baseline data were used, and diuretic treatment status may
Table 3. Estimated Risks*, With 95% Confidence Intervals, for Patients Taking Only Non-PSDs and Those Taking PSDs Relative
to the Risk of Patients Taking No Diuretics at Baseline
Baseline Diuretic Use
None PSD p Value† Non-PSD Only p Value†
Hospitalization for HF 1.00 1.03 (0.75–1.41) 0.86 1.38 (1.11–1.71) 0.003
Death from cardiovascular disease 1.00 0.95 (0.75–1.20) 0.67 1.28 (1.09–1.50) 0.002
Death from all causes 1.00 0.93 (0.75–1.16) 0.52 1.28 (1.19–1.49) 0.0008
Hospitalization for, or death from, HF 1.00 0.99 (0.76–1.30) 0.95 1.31 (1.09–1.57) 0.0004
*Estimated from a multivariate Cox model that included age; gender; study drug allocation (enalapril or placebo); ejection fraction; creatinine level; New York Heart Association
class; systolic and diastolic blood pressure; history of angina, myocardial infarction, hypertension, diabetes, or tobacco use; and baseline use of beta-blockers, aspirin, digoxin,
anticoagulants, anti-arrhythmics, and potassium supplements. †The p value for the chi-square test of the hypothesis that the relative risk is 1.
HF  heart failure; PSD  potassium-sparing diuretic.
Table 2. Event Rates*
Baseline Diuretic Use
p Value†None PSD Only Non-PSD Only Both
Hospitalization for HF 2.2 (237) 4.6 (9) 8.0 (480) 5.0 (47) 0.0008
Death from cardiovascular disease 4.7 (517) 7.1 (15) 12.1 (801) 7.9 (78) 0.0001
Death from all causes 5.4 (594) 7.6 (16) 13.6 (900) 8.8 (87) 105
Hospitalization for, or death from, HF 3.1 (341) 5.7 (12) 9.7 (640) 6.4 (63) 0.0004
*Per 100 patient-years; number of events are shown in parentheses. †For test of equality of event rates for the “PSD only” or
“both” versus “non-PSD only” use patterns.
HF  heart failure; PSD  potassium-sparing diuretic.
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have changed over time. This effect, however, would tend to
make the groups look more, rather than less, alike.
Conclusions. The use of PSDs in HF patients is associated
with a reduced risk of death from, or hospitalization for,
progressive HF, all-cause death, or cardiovascular death,
compared with patients taking only a non-PSD.
Reprint requests and correspondence: Dr. Michael Domanski,
National Heart, Lung, and Blood Institute, 6701 Rocklege Ave-
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Table 4. Estimated Risks* for Patients Taking PSDs Relative to
That for Patients Taking Only Non-PSDs
Baseline Diuretic Use
Non-PSD
Only
PSD Only
or Both
95%
CI
p
Value†
Hospitalization for HF 1.00 0.74 0.55–0.99 0.047
Death from cardiovascular
disease
1.00 0.74 0.59–0.93 0.011
Death from all causes 1.00 0.73 0.59–0.90 0.004
Hospitalization for, or
death from, HF
1.00 0.75 0.58–0.97 0.030
*†Same information as in Table 3 footnote.
CI  confidence interval; HF  heart failure; PSD  potassium-sparing diuretic.
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